124 related articles for article (PubMed ID: 38542184)
21. Pervasiveness of HLA allele-specific expression loss across tumor types.
Filip I; Wang A; Kravets O; Orenbuch R; Zhao J; Perea-Chamblee TE; Manji GA; López de Maturana E; Malats N; Olive KP; Rabadan R
Genome Med; 2023 Feb; 15(1):8. PubMed ID: 36759885
[TBL] [Abstract][Full Text] [Related]
22. Endo-lysosomal assembly variations among human leukocyte antigen class I (HLA class I) allotypes.
Olson E; Ceccarelli T; Raghavan M
Elife; 2023 Feb; 12():. PubMed ID: 36722462
[TBL] [Abstract][Full Text] [Related]
23. Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy.
Alexandraki A; Strati K
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430521
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract][Full Text] [Related]
25. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ; Maurer DM; O'Hara MH; O'Reilly EM; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Yu JX; Pfeiffer SM; Spasic M; Xu J; Gherardini PF; Karakunnel J; Mick R; Alanio C; Byrne KT; Hollmann TJ; Moore JS; Jones DD; Tognetti M; Chen RO; Yang X; Salvador L; Wherry EJ; Dugan U; O'Donnell-Tormey J; Butterfield LH; Hubbard-Lucey VM; Ibrahim R; Fairchild J; Bucktrout S; LaVallee TM; Vonderheide RH
Nat Med; 2022 Jun; 28(6):1167-1177. PubMed ID: 35662283
[TBL] [Abstract][Full Text] [Related]
26. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
[TBL] [Abstract][Full Text] [Related]
27. Functional Differences between Proteasome Subtypes.
Abi Habib J; Lesenfants J; Vigneron N; Van den Eynde BJ
Cells; 2022 Jan; 11(3):. PubMed ID: 35159231
[TBL] [Abstract][Full Text] [Related]
28. Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues.
Kubiniok P; Marcu A; Bichmann L; Kuchenbecker L; Schuster H; Hamelin DJ; Duquette JD; Kovalchik KA; Wessling L; Kohlbacher O; Rammensee HG; Neidert MC; Sirois I; Caron E
iScience; 2022 Feb; 25(2):103768. PubMed ID: 35141507
[TBL] [Abstract][Full Text] [Related]
29. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.
Principe DR; Kamath SD; Korc M; Munshi HG
Pharmacol Ther; 2022 Aug; 236():108111. PubMed ID: 35016920
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
31. The pockets guide to HLA class I molecules.
Nguyen AT; Szeto C; Gras S
Biochem Soc Trans; 2021 Nov; 49(5):2319-2331. PubMed ID: 34581761
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Lee JB; Khan DH; Hurren R; Xu M; Na Y; Kang H; Mirali S; Wang X; Gronda M; Jitkova Y; MacLean N; Arruda A; Alaniz Z; Konopleva MY; Andreeff M; Minden MD; Zhang L; Schimmer AD
Blood; 2021 Jul; 138(3):234-245. PubMed ID: 34292323
[TBL] [Abstract][Full Text] [Related]
33. HLA class-I-peptide stability mediates CD8
Kaseke C; Park RJ; Singh NK; Koundakjian D; Bashirova A; Garcia Beltran WF; Takou Mbah OC; Ma J; Senjobe F; Urbach JM; Nathan A; Rossin EJ; Tano-Menka R; Khatri A; Piechocka-Trocha A; Waring MT; Birnbaum ME; Baker BM; Carrington M; Walker BD; Gaiha GD
Cell Rep; 2021 Jul; 36(2):109378. PubMed ID: 34260940
[TBL] [Abstract][Full Text] [Related]
34. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
35. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
36. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
37. A snapshot of human leukocyte antigen (HLA) diversity using data from the Allele Frequency Net Database.
Gonzalez-Galarza FF; McCabe A; Melo Dos Santos EJ; Jones AR; Middleton D
Hum Immunol; 2021 Jul; 82(7):496-504. PubMed ID: 33755549
[TBL] [Abstract][Full Text] [Related]
38. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F; De Gooijer CJ; van Gulijk M; Lukkes M; Klaase L; Lievense LA; Waasdorp C; Jebbink M; Bootsma GP; Stigt JA; Biesma B; Kaijen-Lambers MEH; Mankor J; Vroman H; Cornelissen R; Baas P; Van der Noort V; Burgers JA; Aerts JG
EBioMedicine; 2021 Feb; 64():103160. PubMed ID: 33516644
[TBL] [Abstract][Full Text] [Related]
39. Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome.
Sturm T; Sautter B; Wörner TP; Stevanović S; Rammensee HG; Planz O; Heck AJR; Aebersold R
J Proteome Res; 2021 Jan; 20(1):289-304. PubMed ID: 33141586
[TBL] [Abstract][Full Text] [Related]
40. MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing.
O'Donnell TJ; Rubinsteyn A; Laserson U
Cell Syst; 2020 Oct; 11(4):418-419. PubMed ID: 33091335
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
